Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553442 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT07553442 is a Phase 2 study that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT07553442, a Phase 2 study, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Interventions
- DRUG Placebo
- DRUG Zilebesiran
- DRUG ALN-AGT01 RVR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07553442
The ClinicalTrials.gov registry entry for NCT07553442 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07553442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07553442 about?
NCT07553442 is a clinical study titled "A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran". The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
What is the current status of trial NCT07553442?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2026-04-27. Estimated completion is 2028-10-01.
What interventions are being tested in trial NCT07553442?
The interventions under investigation include: Placebo (DRUG), Zilebesiran (DRUG), ALN-AGT01 RVR (DRUG).
Who is sponsoring clinical trial NCT07553442?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.